Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Malaria Severity Not Determined Solely by Parasitemia

By LabMedica International staff writers
Posted on 26 May 2014
The relative contributions of such factors as the concentration level of malaria-causing parasites in a person's blood to disease severity and to development of protective immunity are not adequately understood. More...


In areas where transmission is stable, severe malaria is unlikely to occur after five years of age, presumably as a result of immunity, and mathematical models suggest that protection against noncerebral severe malaria develops after one or two infections.

A team of international scientists led by those at the US National Institutes of Health (Rockville, MD, USA) enrolled 882 newborns in the study as part of a longitudinal birth cohort between September 2002 and November 2005, in Muheza (Tanzania). Children were followed for an average of two years and for as long as four years. Children were examined at birth, once every two weeks during infancy, once every month after infancy, and during any illness. Blood smears were collected at all visits, regardless of whether symptoms were present.

Parasitemia was defined as any Plasmodium falciparum detected in a Giemsa-stained blood smear, and high-density infection requiring parenteral treatment was defined as a parasite density of more than 2,500 parasites per 200 white cells. P. falciparum-specific histidine-rich protein 2 plasma concentrations were determined during infection in all available samples from the cohort, which included 475 samples from the children who suffered severe malaria. Samples were tested using an in-house double-site sandwich enzyme-linked immunosorbent assay (ELISA). Hemoglobin type (HbAA, HbAS, and HbSS) was determined by cellulose acetate paper electrophoresis (Helena Laboratories; Beaumont, Texas, USA).

The scientist found that no simple relationship between parasite density and malaria severity emerged. Of the 102 children who did develop severe malaria at least once while enrolled in the study, almost two-thirds had high parasite density, but only mild disease either before or after the episode of severe malaria. This data suggest that one or two mild episodes of malaria are not sufficient to eliminate the risk of severe malaria which is contrary to predictions made by some mathematical models. The team noted that this prospective study is the first to provide direct evidence that severe malaria risk is stable over several infections.

The authors concluded they have provided direct evidence that severe malaria is unlikely to recur but that it commonly occurs after previous infections, including high-density infections. The immunity to severe malaria is not related to improved control of parasite density. The epidemiologic evidence suggests that naturally acquired immunity targets a conserved feature of the various severe-malaria syndromes, such as parasite virulence or host inflammation. The study was published on May 8, 2014, in the New England Journal of Medicine (NEJM).

Related Links:
National Institutes of Health 
Helena Laboratories 



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
New
Nucleic Acid Purification Instrument
QIAsymphony Connect
New
Drug Testing Assays
Atellica DT 250 Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Dr. Olivia Belbin, head of the Molecular Neurodegeneration Group at IR Sant Pau and study corresponding author, with Alba Cervantes (right), first author and IR Sant Pau researcher (Photo courtesy of IR Sant Pau)

Blood Biomarker Detects Alzheimer’s Changes Decades Before Symptoms in Down Syndrome

Alzheimer’s disease can begin altering the brain long before clinical symptoms appear, creating a challenge for early-stage detection and research. People with Down syndrome face a particularly high age-related... Read more

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

Age-Based Genetic Testing May Miss Most Inherited Cancer Risk Variants

Inherited cancer risk can influence diagnosis, treatment planning, and family screening, yet current testing practices often depend on a patient’s age at diagnosis. Many patients undergo germline genetic... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: NMPA approvals for Quanterix HD-X and SR-X instruments and four neurology biomarker assays expand access to ultrasensitive blood-based testing in China (Photo courtesy of Quanterix Corporation)

Regulatory Milestone Expands Access to Blood-Based Neurology Biomarker Testing in China

Quanterix Corporation (Billerica, MA, USA) and Innovita Biological Technology Co., Ltd. (Beijing, China) announced regulatory approvals that expand access to Quanterix SIMOA technology and neurology biomarker... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.